Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design - Archive ouverte HAL Access content directly
Journal Articles Endocrinology, Diabetes & Metabolism Year : 2021

Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design

(1) , (2) , (3, 4, 5, 6, 7) , (3, 4, 5, 6) , (8)
1
2
3
4
5
6
7
8

Abstract

The natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to consider the concomitant presence of NAFLD in drug development for cardiometabolic disorders. This manuscript provides a framework for consideration for future trials examining the inter-relationship between cardiovascular disease and NAFLD.
Fichier principal
Vignette du fichier
Manuscript_HAL.pdf (888.94 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03469195 , version 1 (07-12-2021)

Identifiers

Cite

Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad, Arun J Sanyal. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Endocrinology, Diabetes & Metabolism, 2021, pp.101281. ⟨10.1016/j.diabet.2021.101281⟩. ⟨hal-03469195⟩
91 View
108 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More